GlycoEra AG

GlycoEra AG is a biopharmaceutical company developing biologics for precision immunology. Its approach is to selectively remove disease-driving circulating proteins - autoantibodies among them - rather than suppressing the immune system broadly, with the aim of enabling earlier intervention in autoimmune disease. The company argues that this selectivity may offer a wider therapeutic index, and potentially an improved safety profile, relative to broad-spectrum immunosuppressive therapies.

The lead programme, GE8820, is designed to degrade pathogenic IgG4 autoantibodies and is being advanced toward clinical proof-of-concept. Its stated capability is deep and selective degradation of the pathogenic IgG4 population, in line with the company's emphasis on precision over general immune suppression.

Underlying the pipeline is a protein degradation platform that rapidly, selectively and deeply degrades circulating extracellular protein targets, removing disease-driving proteins while leaving the rest of the immune system intact. The platform's degraders can be produced via a streamlined, one-step recombinant process, relevant to manufacturing as programmes move toward the clinic. Technical domains at the company include targeted and extracellular protein degradation, autoantibody removal, precision immunology, biologics and recombinant protein manufacturing; the therapeutic focus is autoimmune disease and immunology.